6533b827fe1ef96bd1286f35

RESEARCH PRODUCT

Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: a web-based survey

Francesco Paolo RussoFrancesca Romana PonzianiFrancesca Romana PonzianiAlessio AghemoGiuseppe CabibboQuirino LaiMario MasaroneSara MontagneseSalvatore Petta

subject

2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)COVID19Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)macromolecular substancesLiver diseaseInternal medicinePandemicmedicineHumansHCCPandemicsWeb based surveyInternetHepatologybusiness.industrySARS-CoV-2Liver DiseasescirrhosisCOVID19; HCC; SARS-CoV-2; cirrhosis; liver transplantCOVID-19Hepatologymedicine.diseasecirrhosis; COVID19; HCC; liver transplant; SARS-CoV-2; Humans; Internet; Italy; Pandemics; SARS-CoV-2; COVID-19; Liver Diseasesliver transplantItalyEmergency medicinecirrhosis COVID19 HCC liver transplant SARS-CoV-2 Humans Internet Italy Pandemics SARS-CoV-2 COVID-19 Liver Diseasesbusiness

description

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)pandemic has severely limited the clinical activity of most hospitals around the world. A previous survey of the Italian Association for the Study of the Liver (AISF) has demonstrated a negative impact of the first pandemic wave on all inpatient and outpatient hepatologyactivities. Like other countries, Italy has subsequently experienced a second and third wave, which occurred in November 2020 and in March 2021 respectively. During the second and third wave many hospitals had already developed emergency management plans and improved knowledge on the management of mild-moderate COVID19 disease was available. However, it is unknown whether this approach has translated into improved care of patients with chronic liver diseases.

yearjournalcountryeditionlanguage
2021-07-11
10.1111/liv.14998http://hdl.handle.net/11577/3395356